Title Solobacterium moorei 敗血症の 1 例 : 本邦初の特徴について ( 本文 (Fulltext) ) Author(s) 森, 早苗 Citation [ 日本臨床微生物学雑誌 = The journal of the for Clinical Microbiolog

Save this PDF as:

Size: px
Start display at page:

Download "Title Solobacterium moorei 敗血症の 1 例 : 本邦初の特徴について ( 本文 (Fulltext) ) Author(s) 森, 早苗 Citation [ 日本臨床微生物学雑誌 = The journal of the for Clinical Microbiolog"


1 Title Solobacterium moorei 敗血症の 1 例 : 本邦初の特徴について ( 本文 (Fulltext) ) Author(s) 森, 早苗 Citation [ 日本臨床微生物学雑誌 = The journal of the for Clinical Microbiology] vol.[1 Issue Date Rights The Japanese Society for Clinical 物学会 ) Version 出版社版 (publisher version) postprin URL この資料の著作権は 各資料の著者 学協会 出版社等に帰属します

2 Solobacterium moorei 1 1) 1) 1) 1) 1) 1) 2) 1) 2) Solobacterium moorei Prevotella melaninogenica RapID ANAII, API 20A Eggerthella lenta E. lenta 16S rrna Solobacterium moorei 99.6 S. moorei E. lenta a-glucosidase E. lenta S. moorei Key words: Solobacterium moorei 16S rrna, Eggerthella lenta Solobacterium moorei 2000 Kageyama 1) S. moorei Solobacterium 1) 2), 3) S. moorei 3 4 6) S. moorei ( ) TEL: FAX: t mmhg 44 mmhg 75/ 1 WBC /ml CRP mg/dl Vol. 18 No

3 Solobacterium moorei Peripheral blood Blood chemistry RBC /ml TP 5.8 g/dl Hb 10.3 g/dl AST 59 IU/L Ht 29.2 ALT 55 IU/L LD 160 IU/L WBC /ml Total-Bill 0.3 mg/dl Seg 83.4 UN 22.6 mg/dl Lym 8.4 Cr 0.8 mg/dl Mono 3.0 Na 130 meq/l Eosino 2.7 K 3.8 meq/l Baso 0.7 Cl 87 meq/l Plt /ml CRP mg/dl pazufloxacin 1,000 mg/day 7 micafungin 50 mg/day 16 7 cefozopran 1 g/day 7 14 cefpirome 1 g/ day CRP 9 23 mg/dl F 93F BD BACTEC 9120 BD ) BACTEC F Bartholomew & Mittwer M 2) 2 93F II 5 TSA BD BY BYCHO BD BTB BTB BD ABHK ABHK NV ABHK NVABHK BBE BBE BD TSA BYCHO 35 7 CO 2 BTB 35 ABHK NVABHK 35 3) ABHK RID Zyme IND-S RapID ANAII API 20 A CRYSTAL ANR BD 16S rrna RapID ANAII 4) MIC MIC 5) S. moorei Eggerthella lenta ATCC RapID ANAII API 20A 1 E. lenta ATCC43055 S. moorei ABHK 48 Bartholomew & Mittwer RapID ANAII API 20A CRYSTAL ANR E. lenta Vol. 18 No

4 238 1 Bartholomew & Mittwer 1, ) 1 2) TSA BYCHO BTB 48 2 ABHK 1mm 2 ABHK NVABHK BBE 2 3) RapID ANAII , 91.3 Eggerthella lenta (Wade et al., 1999) 7) API20A E. lenta , 94.2 CRYSTAL ANR Atopobium minutum Solobacterium moorei 48 ABHK 78.9 CRYSTAL ANR RapID ANAII API 20A E. lenta E. lenta 16S rrna S. moorei (JCM T ) Vol. 18 No

5 Solobacterium moorei Solobacterium moorei Antimicrobial agent MIC (mg/ml) Ampicillin 0.06 Penicillin G 0.06 Piperacillin 0.5 Cefmetazole 0.5 Ceftizoxime 0.5 Cefozopran 0.5 Flomoxef 0.5 Imipenem 0.12 Amoxicillin/clavalanic acid 0.18 Clindamycin 0.06 Minocycline 0.12 Chloramphenicol 4 Sparfloxacin 0.25 S. moorei BBE Prevotella melaninogenica RapID ANAII P. melaninogenica ) S. moorei 2 MIC chloramphenicol 4 mg/ml sparfloxacin 0.25 mg/ml MIC cefozopran MIC 0.5 mg/ml P. melaninogenica sparfloxacin 2 mg/ml 5) S. moorei Eggerthella lenta ATCC E. lenta S. moorei 3 RapID ANAII S. moorei arginine, serine a-glucosidase E. lenta arginine serine a-glucosidase RapID ANAII E. lenta ATCC 1), 6), 8) S. moorei 3 API 20A S. moorei E. lenta E. lenta ATCC E. lenta CRYSTAL ANR S. moorei E. lenta ATCC arginine, serine, glycine, ala- 3 Solobacterium moorei (A) Eggerthella lenta ATCC43055 (B) S. moorei E. lenta Bartholomew & Mittwer 1,000 Vol. 18 No

6 240 3 Eggerthella lenta ATCC43055 RapID ANAII Biochemical reaction or enzyme Isolate Results E. lenta ATCC43055 Published S. moorei strain a Urease p-nitrophenyl-b,9-disaccharide (b-disaccharidase) NT p-nitrophenyl-a,a-arabinoside (a-arabinosidase) o-nitrophenyl-b,9-galactoside (b-galactosidase) p-nitrophenyl-a,9-glucoside (a-glucosidase) p-nitrophenyl-b,9-glucoside (b-glucosidase) p-nitrophenyl-a,9-galactoside (a-galactosidase) p-nitrophenyl-a,a-fucoside (a-fucosidase) p-nitrophenyl-n-acetyl-b,9-glucosaminide (N-Acetyl-glucosaminidase) p-nitrophenylphosphate NT Leucyl-glycine-b-naphthylamide NT Glicine-b-naphthylamide NT Proline-b-naphthylamide (Proline arylamidase) Phenylalanine-b-naphthylamide NT Argnine-b-naphthylamide (Arginine dehydrogenase) Serine-b-naphthylamide NT Pyrrolidonyl-b-naphtylamide NT Indole production Nitrate reduction Catalase a NT: not tested nine, pyroglutamic acid, lysine, methionine, phenylalanine, leucine 2 E. lenta 2 3 Eubacterium E. lenta 9) E. lenta 10) chloramphenicol sparfloxacin MIC MIC E. lenta E. lenta Solobacterium moorei S. moorei S. moorei E. lenta API 20A CRYSTAL ANR E. lenta API 20A 20 Vol. 18 No

7 Solobacterium moorei RapID ANAII S. moorei a- glucosidase E. lenta a-glucosidase CRYSTAL ANR RapID ANAII CRYSTAL ANR S. moorei CRYS- TAL ANR S. moorei RapID ANAII a-glucosidase Eubacterium 11) ) ) S. moorei S. moorei 3 S. moorei S rrna S. moorei E. lenta S. moorei Vol. 18 No

8 Vol. 18 No Solobacterium moorei Underlying Author Country Age Sex Year Portal of entry disease Infection type Identification Treatment Outcome copathogens Present study Japan 60 male 2008 Larynx cancer Abscessus of cervix Mixed P. melaninogenica Detry, G., et al. Anaerobe 12: Susanna, K. P. Lau, et al. JCM 44: Claire A. Martin, et al. JMCR1: 40 Belgium 67 male 2006 Multiple myeloma Abscessus of root portion of the tooth Hong Kong 43 female 2006 Cervix cancer Acute proctitis a England (UK) 37 male 2007 Intravenous drug user (mucosa) Abscessus of injection insertion site Mixed Oral flora Mixed Unclear Mixed Bacteroides sp. Fusobacterium sp. 16S rrna gene PZFX CZOP Death 16S rrna gene CFPM AMK Cure 16S rrna gene PIPC/TAZ ND 16S rrna gene Metronidazole PCG Cure a by radiation therapy; ND: no data; PZFX: pazufloxacin; CZOP: cefozopran; CFPM: cefepime; AMK: amikacin; PIPC/TAZ: piperacillin/tazobactam; PCG: benzylpenicillin

9 Solobacterium moorei ) Kageyama, A., Y. Benno Phylogenetic and phenotypic characterization of some Eubacterium-like isolates from human feces: Description of Solobacterium moorei gen. nov., sp. nov. Microbiol. Immunol. 44: ) Kazor, C. E., P. M. Mitchell, A. M. Lee, et al Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J. Clin. Microbiol. 41: ) Haraszthy, V. I., J. J. Zambon, P. K. Sreenivasan, et al Identification of oral bacterial species associated with halitosis. J. Am. Dent. Assoc. 138(8): ) Detry, G., D. Pierard, K. Vandoorslaer, et al Septicemia due to Solobacterium moorei in a patient with multiple myeloma. Anaerobe 12: ) Susanna, K. P. Lau, J. L. Teng, K. W. Leung, et al Bacteremia caused by Solobacterium moorei in a patientwith acute proctitis and carcinoma of the cervix. J. Clin. Microbiol. 44: ) Claire, A. Martin, Rohan S. Wijesurendra, Colin D. R. Borland, et al Femoral vein thrombophlebitis and septic pulmonary embolism due to a mixed anaerobic infection including Solobacterium moorei: A case report. J. Med., Case Reports 1: 40. 7) Wade, W. G., J. Downes, D. Dymock, et al The family Coriobacteriaceae: reclassification of Eubacterium exiguum (Poco et al., 1996) and Peptostreptococcus heliotrinreducens (Lanigan, 1976) as Slackia exigua gen. nov., comb. nov. and Slackia heliotrinireducens gen. nov., comb. nov., and Eubacterium lentum (Prevot 1938) as Eggerthella lenta gen. nov., comb. nov. IJSB 49: ) Eija Könönen, William G. Wade Propionibacterium, Lactobacillus, Actinomyces, and Other Non-Spore-Forming Anaerobic Gram- Positive Rods. p , In: Manual of Clinical Microbiology, 9 th ed. (P. R. Murray, E. J. Baron, M. A. Pfaller, et al. ed.), American Society for Microbiology, Washington, D.C. 9) Adriana Mosca, Paula Summanen, Sydney M. Finegold, et al Cellular Fatty Acid Composition, Soluble-Protein Profile, and Antimicrobial Resistance Pattern of Eubacterium lentum. J.Clin. Microbiol. 36: ) (5) p ) Bernard J. Moncla, Sharon L. Hillier Peptostreptococcus, Propionibacterium, Lactobacillus, Actinomyces, and Other Non-Spore- Forming Anaerobic Gram-Positive Bacteria. p , In: Manual of Clinical Microbiology, 8 th ed. (P. R. Murray, E. J. Baron, M. A. Pfaller, et al. ed.), American Society for Microbiology, Washington, D.C. 12) : ) p Vol. 18 No

10 244 Solobacterium moorei as a Cause of Sepsis in a Patient with Larynx Cancer: A First Case Report in Japan and Characterization of the Isolate Sanae Mori, 1) Tomohisa Watari, 1) Atushi Yasuda, 1) Sachiko Miura, 1) Takashi Ogaya, 1) Munehiro Hatanaka, 1) Kiyofumi Ohkusu 2) 1) Department of Clinical Laboratory, Kitami Red Cross Hospital 2) Department of Microbiology, Gifu University Graduate School of Medicine Herein we report the first Japanese case of sepsis caused by Solobacterium moorei, an anaerobic, non-sporulated Gram-positive bacillus in a patient with terminal-stage laryngeal cancer. A 60-year-old male was admitted to our hospital with high fever and fatigue. He had a long-lasting medical history and had a subcutaneous neck abscess. A set of blood culture was obtained with the BACTEC Aerobic/92F and Anaerobic/93F resin bottles. After 2 days, Gram-variable polymorphic rods and Prevotella melaninogenica grew from only the anaerobic culture vial. The RapID ANA system indicated that the Gram-variable polymorphic rod was 91.3 likely to be Eggerthella lenta. The API 20A system also showed that it was 94.2 likely to be E. lenta. However, we hesitated to identify it as E. lenta due to the discrepancies between results of our biochemical tests and of those reported in the literature. We therefore performed PCR amplification and DNA sequencing of the 16S rrna gene of the isolate. A sequence of 1450 bp was found to be 99.6 homologous to the S. moorei type strain sequence (AY044915), indicating that the isolate was a strain of S. moorei, note. lenta. Tofurther characterize the isolate, we compared it with E. lenta strain (ATCC43055). It was found that they share the same phenotypical characteristics, except the isolate was negative for the catalase and the nitrate reduction tests, and positive for the a-glucosidase test. Thus, it is likely that S. moorei and E. lenta would be di#erentiated by these three reactions in clinical microbiology laboratory. 24 Vol. 18 No